Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia

Respirology

Volumn 17, Issue 2, 2012, Pages 330-336

  Kasamatsu, Yu ^a,b   Yamaguchi, Toshimasa ^c   Kawaguchi, Takashi ^c   Tanaka, Nagaaki ^c   Oka, Hiroko ^c   Nakamura, Tomoyuki ^b   Yamagami, Keiko ^b   Yoshioka, Katsunobu ^b   Imanishi, Masahito ^b  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c Osaka City Juso Hospital   (Japan)

Author keywords

A DROP; C reactive protein; community acquired pneumonia; procalcitonin; semi quantitative procalcitonin test

Indexed keywords

C REACTIVE PROTEIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; MACROLIDE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE, DEHYDRATION, RESPIRATORY FAILURE, ORIENTATION DISTURBANCE, PRESSURE SCALE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION, UREA, RESPIRATORY RATE, BLOOD PRESSURE, AGE 65 SCALE; DIAGNOSTIC KIT; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; IMMUNOASSAY; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA SEVERITY INDEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SEMI QUANTITATIVE PROCALCITONIN TEST;

AGED; BIOLOGICAL MARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; IMMUNOASSAY; JAPAN; MALE; PNEUMONIA, BACTERIAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84863053491     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02101.x     Document Type: Article

References (29)

1. File TM, Marrie TJ,. Burden of community-acquired pneumonia in North American adults. Postgrad. Med. 2010; 122: 130-41.
2. Ewig S, Birkner N, Strauss R, et al,. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-9.
3. Statistics and Information Department. Vital Statistics 2008. Ministry of Health, Labor and Welfare, Tokyo, 2009.
4. Fine MJ, Auble TE, Yealy DM, et al,. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243-50. (Pubitemid 27044625)
5. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (Suppl. 4): IV1-64.
6. Yanagihara K, Kohno S, Matsusima T,. Japanese guidelines for the management of community-acquired pneumonia. Int. J. Antimicrob. Agents 2001; 18 (Suppl. 1): S45-S48. (Pubitemid 33713503)
7. Assicot M, Gendrel D, Carsin H, et al,. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-18. (Pubitemid 23066085)
8. Aikawa N, Fujishima S, Endo S, et al,. Multicenter prospective study of procalcitonin as an indicator of sepsis. J. Infect. Chemother. 2005; 11: 152-9. (Pubitemid 40933683)
9. Quintana G, Medina YF, Rojas C, et al,. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J. Clin. Rheumatol. 2008; 14: 138-42.
10. Meisner M, Brunkhorst FM, Reith HB, et al,. Clinical experiences with a new semi-quantitative solid phase immunoassay for rapid measurement of procalcitonin. Clin. Chem. Lab. Med. 2000; 38: 989-95.
11. Brunkhorst FM, Al-Nawas B, Krummenauer F, et al,. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin. Microbiol. Infect. 2002; 8: 93-100. (Pubitemid 34993769)
12. Brunkhorst FM, Heinz U, Forycki ZF,. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998; 24: 888-9.
13. Stolz D, Christ-Crain M, Bingisser R, et al,. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19. (Pubitemid 46122969)
14. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al,. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-7. (Pubitemid 38264177)
15. Muller B, Harbarth S, Stolz D, et al,. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis. 2007; 7: 10.
16. Boussekey N, Leroy O, Alfandari S, et al,. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006; 32: 469-72. (Pubitemid 43289660)
17. Boussekey N, Leroy O, Georges H, et al,. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005; 33: 257-63. (Pubitemid 41152186)
18. Korppi M, Remes S, Heiskanen-Kosma T,. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr. Pulmonol. 2003; 35: 56-61. (Pubitemid 36009014)
19. Hirakata Y, Yanagihara K, Kurihara S, et al,. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2008; 61: 170-4. (Pubitemid 351680368)
20. Menendez R, Martinez R, Reyes S, et al,. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-91.
21. Kruger S, Ewig S, Marre R, et al,. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J. 2008; 31: 349-55.
22. Okimoto N, Hayashi Y, Ishiga M, et al,. Procalcitonin and severity of community-acquired pneumonia. J. Infect. Chemother. 2009; 15: 426-7.
23. Menendez R, Martinez R, Reyes S, et al,. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987-92.
24. Kruger S, Ewig S, Papassotiriou J, et al,. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir. Res. 2009; 10: 65.
25. Tseng JS, Chan MC, Hsu JY, et al,. Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology 2008; 13: 505-9.
26. Niederman MS,. Making sense of scoring systems in community acquired pneumonia. Respirology 2009; 14: 327-35.
27. Smith RP, Lipworth BJ, Cree IA, et al,. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995; 108: 1288-91.
28. Heiskanen-Kosma T, Korppi M,. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. Scand. J. Infect. Dis. 2000; 32: 399-402. (Pubitemid 30612155)
29. Briel M, Schuetz P, Mueller B, et al,. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch. Intern. Med. 2008; 168: 2000-7.